The FDA has granted a priority review to Celgene's (CELG +2.1%) Revlimid drug for patients with...

|About: Celgene Corporation (CELG)|By:, SA News Editor

The FDA has granted a priority review to Celgene's (CELG +2.1%) Revlimid drug for patients with relapsed or refractory mantle cell lymphoma (MCL) after prior therapy. Revlimid, in combination with the steroid dexamethasone, has also won approval from China's State Food & Drug Administration for use in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. (PR)